Praxis Precision Medicines, Inc.
corporate_fare Company Profile
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for PRAX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 14 rated 8 or above. Recent SEC coverage for PRAX spans 8-K, 10-Q, 10-K.
Recent high-impact activity:
- Praxis Sets $20B+ Peak Sales Target, Discloses Launch Pricing and Two PDUFA Dates
- Praxis Posts Q3 Loss of $94.2M; Two FDA Decisions Due by Late January 2027
- Praxis Posts $94.2M Q3 Loss, $1.3B Cash Ahead of Two FDA Decisions
- Praxis Precision Medicines Extends Cash Runway into 2028, Reports Q2 Financials
- Praxis Q2: $1.4B Cash, Two PDUFAs on Track, No FDA Red Flags
Financial Snapshot
Short Interest & Short Volume
8.69 days to coverFINRA reported short interest of 4,207,692 shares in PRAX as of the October 30, 2026 settlement, a 7.3% increase from the prior period — about 8.7 days to cover at its recent average daily volume. On November 20, 2026, 66.5% of PRAX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.